Homepage
Healthcare · Biotechnology · United States · Updated May 11, 1:06am
$0.57
Price
$14.6M
Market Cap
19
Employees
0.87
Beta
Kuk Hyoun Hwang
CEO
Business Description
OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.
Business History
Price Overview
Last updated: May 11, 2026 1:50pm (just now)$0.56
-0.01 (-2.24%)
Day Range
$0.56 – $0.59
52-Week Range
$0.38 – $1.79
50-Day MA
$0.53
200-Day MA
$0.60
Volume
944,311.00
Share Structure
Outstanding
25,672,788.00
Float
7,850,482.00
Free Float
30.6%
Moderate free float
— 30.6% of shares trade freely, ~69.4% held by insiders/institutions
Reasonable but insiders still hold a significant stake. This can be positive (skin in the game) but may limit liquidity during sell-offs.
Small absolute float (7.9M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.14
Stock Price: $0.57
EPS (Diluted): -4.02
EPS (Diluted): -4.02
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.03
Stock Price: $0.57
Total Equity: $77.64M
Shares: 4,482,000
Total Equity: $77.64M
Shares: 4,482,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.60
Market Cap: $14.65M
Total Debt: $4.34M
Cash: $1.70M
EBITDA: -$19.08M
Total Debt: $4.34M
Cash: $1.70M
EBITDA: -$19.08M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$5.2M
Market Cap: $14.65M
Total Debt: $4.34M
Cash: $1.70M
Total Debt: $4.34M
Cash: $1.70M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
20.4%
Gross Profit: $592,905
Revenue: $2.91M
Revenue: $2.91M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-631.0%
Operating Income: -$18.34M
Revenue: $2.91M
Revenue: $2.91M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-619.8%
Net Income: -$18.01M
Revenue: $2.91M
Revenue: $2.91M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-27.9%
Net Income: -$18.01M
Total Equity: $77.64M
Total Equity: $77.64M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-11.6%
Operating Income: -$18.34M
Tax Rate: 6.3%
Equity: $77.64M
Total Debt: $4.34M
Cash: $1.70M
Tax Rate: 6.3%
Equity: $77.64M
Total Debt: $4.34M
Cash: $1.70M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.16
Current Assets: $2.82M
Current Liabilities: $17.17M
Current Liabilities: $17.17M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.06
Short-Term Debt: $4.34M
Long-Term Debt: $0.00
Total Debt: $4.34M
Total Equity: $77.64M
Long-Term Debt: $0.00
Total Debt: $4.34M
Total Equity: $77.64M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.65
Revenue: $2.91M
Shares: 4,482,000
Shares: 4,482,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$17.32
Total Equity: $77.64M
Shares: 4,482,000
Shares: 4,482,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.01
Operating CF: -$4.33M
CapEx: -$176,385
Shares: 4,482,000
CapEx: -$176,385
Shares: 4,482,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.57
Stock Price: $0.57
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$18.01M
Net Income: -$18.01M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares OSRH against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.5M | $2.9M |
| Cost of Revenue | $0 | $0 | $0 | $2.7M | $2.3M |
| Gross Profit | $0 | $0 | $0 | $811,236 | $592,905 |
| Operating Expenses | $3,308 | $35,388 | $1.8M | $12.5M | $18.9M |
| Operating Income | $-3,308 | $-35,388 | -$1.8M | -$11.7M | -$18.3M |
| Net Income | $-3,308 | $-35,388 | $403,780 | -$10.3M | -$18.0M |
| EBITDA | $233,250 | $193,097 | $3.7M | -$2.2M | -$19.1M |
| EPS | $0.00 | $0.00 | $0.07 | $-0.54 | $-4.02 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4,757 | $2,238 | $15,419 | $66,135 | $1.7M |
| Total Current Assets | $4,757 | $3,511 | $22,627 | $455,398 | $2.8M |
| Total Assets | $705,087 | $95,982 | $36.6M | $2.3M | $171.2M |
| Current Liabilities | $707,207 | $4,658 | $2.0M | $6.7M | $17.2M |
| Long-Term Debt | $0 | $101 | $0 | $0 | $0 |
| Total Liabilities | $707,207 | $17,216 | $4.1M | $8.8M | $44.2M |
| Total Equity | $-2,120 | $78,766 | $32.5M | -$6.5M | $77.6M |
| Retained Earnings | $-27,120 | $42 | -$3.9M | -$8.3M | -$37.2M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-461 | $-410 | $-818,766 | -$2.2M | -$4.3M |
| Capital Expenditure | $0 | $-62 | $-4 | $0 | $-176,385 |
| Free Cash Flow | $-461 | $-472 | $-818,770 | -$2.2M | -$4.5M |
| Acquisitions (net) | $0 | $1,415 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$36.0M | -$36.2M | $0 |
| Net Change in Cash | $-57,896 | $1,960 | $-109,082 | $50,716 | $1.4M |
Analyst Estimates (Annual)
| Metric | 2025 | 2026 | 2027 |
|---|---|---|---|
| Revenue |
$3.4M $3.4M – $3.4M
|
$3.1M $3.1M – $3.1M
|
$71.7M $71.7M – $71.7M
|
| EBITDA |
$951,233 $951,233 – $951,233
|
$866,292 $866,292 – $866,292
|
$19.9M $19.9M – $19.9M
|
| Net Income |
-$4.3M -$4.3M – -$4.3M
|
-$4.9M -$4.9M – -$4.9M
|
$0 |
| EPS | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | -17.7% |
| Gross Profit Growth | — | — | — | -26.9% |
| Operating Income Growth | -969.8% | -5,074.1% | -538.6% | -56.8% |
| Net Income Growth | -969.8% | +1,241.0% | -2,658.1% | -74.4% |
| EBITDA Growth | -17.2% | +1,826.3% | -157.8% | -787.2% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-26 | Kim Yeiseok | 0.00 | $0.00 | $0 | |
| 2025-09-17 | Fierz Reto Kaspar | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Cho Joong Myung | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Barberis Alcide | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Kim Sang Harry | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Bang Gihyoun | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Jee Hyuk Joo | 0.00 | $0.00 | $0 | |
| 2025-02-14 | Bellevue Global Life Science Investors LLC | J-Other | 43,000.00 | $0.00 | $0 |
| 2025-02-14 | Hwang Kuk Hyoun | J-Other | 3,123,970.00 | $0.00 | $0 |
| 2025-02-14 | Hwang Kuk Hyoun | J-Other | 7,531,634.00 | $0.00 | $0 |
| 2025-02-14 | Hwang Kuk Hyoun | J-Other | 43,000.00 | $0.00 | $0 |
| 2025-02-14 | Bellevue Capital Management LLC | 0.00 | $0.00 | $0 | |
| 2025-02-14 | BCM Europe AG | 0.00 | $0.00 | $0 | |
| 2024-06-23 | Kim Sang Hyun | 0.00 | $0.00 | $0 | |
| 2024-05-27 | Lee Phil Geon | 0.00 | $0.00 | $0 | |
| 2023-03-23 | Hwang Kuk Hyoun | J-Other | 20,000.00 | $0.00 | $0 |
| 2023-03-23 | Hwang Kuk Hyoun | J-Other | 20,000.00 | $11.50 | $230,000 |
| 2023-03-23 | Yoo David Jin | A-Award | 20,000.00 | $0.00 | $0 |
| 2023-03-23 | Yoo David Jin | A-Award | 20,000.00 | $11.50 | $230,000 |
| 2023-03-23 | Bellevue Global Life Science Investors LLC | J-Other | 20,000.00 | $0.00 | $0 |
No community reviews yet for OSRH.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27